Novavax, Inc. (NASDAQ: NVAX) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Novavax, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.96, Novavax, Inc. trades at 3.2x sales. Over the last twelve months it generated about $411M of revenue and a net loss of $76M. It runs a gross margin of 77.3%, an operating margin of -19.6% and a net margin of -18.6%. It shows return on equity of 45.1%, return on invested capital of -14.4% and a free cash flow yield of -18.8%. On the balance sheet: a debt-to-equity ratio of -1.36 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $6.20 to $13.39, with a beta of 2.72.
Novavax, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 16 Buy, 3 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Novavax, Inc. (NVAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 37.2% / 30% · Interest income / Revenue 9.08% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 17.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 37.2% / 33% · Receivables / Mkt Cap (36m) 2.94% / 49% · Interest income / Revenue 9.08% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 17.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 37.2% / 33.33% · Receivables / Mkt Cap (24m) 2.94% / 33.33% · Interest income / Revenue 9.08% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 27.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 70.6% / 33.33% · Receivables / Avg Assets (4Q) 4.86% / 33.33% · Interest income / Revenue 9.08% / 5% | Fail |
| FTSE | Debt / Total Assets 32.9% / 33.33% · (Cash+ST Inv) / Total Assets 70.1% / 33.33% · (Cash+Recv) / Total Assets 75.6% / 33.33% · Interest income / Revenue 9.08% / 5% | Fail |
No. As of September 2026, Novavax, Inc. (NVAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Novavax, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 9.08% of each dividend: Novavax, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.